Company intelligence / Profile preview

Eclypia

France

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

Eclypia is developing a non-invasive, continuous glucose monitoring device based on photonics technology. The device aims to provide real-time, reliable blood glucose measurements without the need for finger pricks. The company has developed proprietary algorithms for glycemia prediction and holds 25 patents protecting its core technology. Clinical validation appears to be ongoing; no published pivotal clinical trial results or regulatory approvals are noted as of early 2025[1][2].

Therapeutic areas: Endocrinology
Modalities: DeviceNon-invasive monitoring technologyPhotonics-based sensor system (for glucose)
Industry: Physiological Monitoring

Partnerships

Eclypia collaborates with CEA-Leti, a major French research organization specializing in micro-nanotechnologies and health tech innovation support[2][4].

Beyond the preview

Go deeper on Eclypia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eclypia.

Explore the full profile